Biotech | March 01, 2022
South Korea's OCI acquires 11% stake in Bukwang Pharmaceutical
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
The method shows the removal of seven types of PFAS – even when all of them are found in the same unit of fluid – at a level of efficiency that approaches 90%, and it does so within a few minutes
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
Appoints Dr Rafiq Hasan as CEO
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
Subscribe To Our Newsletter & Stay Updated
